N-(1S-cyanomethylaminoformyl-2-cyclohexylethyl)-3-methylbenzamide | 225120-05-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1S-cyanomethylaminoformyl-2-cyclohexylethyl)-3-methylbenzamide
• 英文别名: N-(1S-cyanomethylcarbamoyl-2-cyclohexylethyl)-3-methylbenzamide；N-[(2S)-1-(cyanomethylamino)-3-cyclohexyl-1-oxopropan-2-yl]-3-methylbenzamide
• CAS: 225120-05-8
• 化学式: C₁₉H₂₅N₃O₂
• 分子量: 327.426
• InChiKey: URDRFGGALQGMFV-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  82
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Novel compounds and compositions as protease inhibitors
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：US20030096796A1

  公开（公告）日：2003-05-22

  The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及新型N-氰甲基酰胺，其为半胱氨酸蛋白酶抑制剂，其药学上可接受的盐和N-氧化物，其作为治疗剂的用途以及其制备方法。
• NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS
  申请人：Bryant M. Clifford

  公开号：US20070015755A1

  公开（公告）日：2007-01-18

  The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新型的N-氰甲基酰胺，它们是半胱氨酸蛋白酶抑制剂，其医药上可接受的盐和N-氧化物，以及它们作为治疗剂的用途和制造方法。
• N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1178958A2

  公开（公告）日：2002-02-13
• US6455502B1
  申请人：——

  公开号：US6455502B1

  公开（公告）日：2002-09-24
• [EN] NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSES ET COMPOSITIONS UTILISES EN QUALITE D'INHIBITEURS DE PROTEASES
  申请人：AXYS PHARM INC

  公开号：WO2000055125A2

  公开（公告）日：2000-09-21

  The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.